GEORGE DIGGS: Open Payments
NPI 1699700880 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,087 in 118 payments from 13 companies in 2025. Trend: 2023 $1,752 · 2024 $1,609 · 2025 $2,087
Food & beverage: $1,976Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $420 |
| Neurocrine BioSciences, Inc. | 16 | $408 |
| Alkermes, Inc. | 18 | $331 |
| Otsuka America Pharmaceutical, Inc. | 13 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $167 |
| Vanda Pharmaceuticals Inc. | 7 | $163 |
| E.R. Squibb & Sons, L.L.C. | 11 | $158 |
| Janssen Pharmaceuticals, Inc | 4 | $71 |
| ABBVIE INC. | 3 | $60 |
| Braeburn Inc. | 2 | $42 |
Products named: INGREZZA, ARISTADA, UZEDY, REXULTI, CAPLYTA, FANAPT, COBENFY, LYBALVI.
Industry payments across LA — which companies pay providers there.
